1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Domain Therapeutics - Product Pipeline Review - 2013

Domain Therapeutics - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 31 pages

Domain Therapeutics - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “Domain Therapeutics - Product Pipeline Review - 2013” provides data on the Domain Therapeutics’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Domain Therapeutics’s corporate website, SEC filings, investor presentations and featured press releases, both from Domain Therapeutics and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- Domain Therapeutics - Brief Domain Therapeutics overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Domain Therapeutics human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Domain Therapeutics with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Domain Therapeutics’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Domain Therapeutics’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Domain Therapeutics in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Domain Therapeutics’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Domain Therapeutics.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Domain Therapeutics and identify potential opportunities in those areas.

Table Of Contents

Domain Therapeutics - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 4
List of Figures 4
Domain Therapeutics Snapshot 5
Domain Therapeutics Overview 5
Key Information 5
Key Facts 5
Domain Therapeutics - Research and Development Overview 6
Key Therapeutic Areas 6
Domain Therapeutics - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Domain Therapeutics - Pipeline Products Glance 10
Domain Therapeutics - Early Stage Pipeline Products 10
Pre-Clinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
Domain Therapeutics - Drug Profiles 12
Drug Targeting GPR88 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
DT-1133 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
DT-1687 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
DT-2208 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
DT-2228 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
DT-XXXX 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
mGluR2-PAM 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
mGluR3 NAM 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Orphan GPCR 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Domain Therapeutics - Pipeline Analysis 21
Domain Therapeutics - Pipeline Products by Therapeutic Class 21
Domain Therapeutics - Pipeline Products by Route of Administration 23
Domain Therapeutics - Pipeline Products By Mechanism of Action 24
Domain Therapeutics - Recent Pipeline Updates 26
Domain Therapeutics - Dormant Projects 28
Domain Therapeutics - Locations And Subsidiaries 29
Head Office 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31

List of Tables


Domain Therapeutics, Key Information 5
Domain Therapeutics, Key Facts 5
Domain Therapeutics - Pipeline by Indication, 2013 7
Domain Therapeutics - Pipeline by Stage of Development, 2013 8
Domain Therapeutics - Monotherapy Products in Pipeline, 2013 9
Domain Therapeutics - Pre-Clinical, 2013 10
Domain Therapeutics - Discovery, 2013 11
Domain Therapeutics - Pipeline By Therapeutic Class, 2013 22
Domain Therapeutics - Pipeline By Route of Administration, 2013 23
Domain Therapeutics - Pipeline Products By Mechanism of Action, 2013 25
Domain Therapeutics - Recent Pipeline Updates, 2013 26
Domain Therapeutics - Dormant Developmental Projects,2013 28

List of Figures


Domain Therapeutics - Pipeline by Indication, 2013 7
Domain Therapeutics - Pipeline by Stage of Development, 2013 8
Domain Therapeutics - Monotherapy Products in Pipeline, 2013 9
Domain Therapeutics - Pipeline By Therapeutic Class, 2013 21
Domain Therapeutics - Pipeline By Route of Administration, 2013 23
Domain Therapeutics - Pipeline Products By Mechanism of Action, 2013 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.